MX360449B - Vacunas para el virus del papiloma humano y metodos para su uso. - Google Patents

Vacunas para el virus del papiloma humano y metodos para su uso.

Info

Publication number
MX360449B
MX360449B MX2014004537A MX2014004537A MX360449B MX 360449 B MX360449 B MX 360449B MX 2014004537 A MX2014004537 A MX 2014004537A MX 2014004537 A MX2014004537 A MX 2014004537A MX 360449 B MX360449 B MX 360449B
Authority
MX
Mexico
Prior art keywords
hpv
vaccines
disclosed
methods
same
Prior art date
Application number
MX2014004537A
Other languages
English (en)
Other versions
MX2014004537A (es
Inventor
B Weiner David
Yan Jian
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2014004537A publication Critical patent/MX2014004537A/es
Publication of MX360449B publication Critical patent/MX360449B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una molécula de ácido nucleico caracterizada porque comprende una secuencia de nucleótidos que codifica un antígeno de HPV de E6/E7 de fusión de consenso seleccionado del grupo que consiste en: SEQ ID NO: 1, fragmentos que comprenden al menos 786 nucleótidos de la SEQ ID NO: 1 y que tienen al menos 90% de identidad con la SEQ ID NO: 1 y en donde los fragmentos codifican inmunógenos que mejoran respuestas inmunes contra HPV; y combinaciones de éstas.
MX2014004537A 2011-10-12 2011-10-12 Vacunas para el virus del papiloma humano y metodos para su uso. MX360449B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/055932 WO2013055326A2 (en) 2011-10-12 2011-10-12 Vaccines for human papilloma virus and methods for using the same

Publications (2)

Publication Number Publication Date
MX2014004537A MX2014004537A (es) 2014-08-01
MX360449B true MX360449B (es) 2018-11-01

Family

ID=48082701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004537A MX360449B (es) 2011-10-12 2011-10-12 Vacunas para el virus del papiloma humano y metodos para su uso.

Country Status (9)

Country Link
EP (2) EP2750703B1 (es)
KR (5) KR20140076613A (es)
CN (3) CN107723299B (es)
AU (2) AU2011378812B2 (es)
CA (2) CA3161127A1 (es)
EA (1) EA033242B1 (es)
MX (1) MX360449B (es)
WO (1) WO2013055326A2 (es)
ZA (1) ZA201402553B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034056B1 (ru) 2013-03-12 2019-12-23 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Усовершенствованные вакцины против вируса папилломы человека и способы их применения
BR112022007615A2 (pt) * 2019-10-24 2022-07-12 Univ Pennsylvania Método para tratar ou prevenir papilomatose respiratória recorrente, e, sequência de nucleotídeo
CN111647067B (zh) * 2020-07-02 2021-06-04 北京广未生物科技有限公司 AP-2alpha抗体联合用药用于制备治疗宫颈癌的药物中的用途
MX2023006038A (es) * 2020-11-25 2023-07-11 Precigen Inc Vacunas contra el virus del papiloma humano y usos de estas para enfermedades asociadas a hpv.
US20250352632A2 (en) * 2021-05-19 2025-11-20 Daiichi Sankyo Company, Limited Hpv infectious disease vaccine
CN120249336B (zh) * 2025-06-04 2025-08-26 艾棣维欣(苏州)生物制药有限公司 编码人乳头瘤病毒抗原的重组dna分子、dna疫苗及应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
NL9020389A (nl) 1989-03-08 1991-12-02 Health Research Inc Systeem voor het in de gastheer selecteren van recombinant-pokkenvirussen.
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
ES2090129T3 (es) 1989-03-31 1996-10-16 Univ Washington Vacunas que contienen microorganismos tipo phop avirulentos.
DE69016956T2 (de) 1989-12-04 1995-07-20 Akzo Nobel Nv Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
WO1992005248A1 (en) * 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5864027A (en) 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995028942A1 (en) * 1994-04-26 1995-11-02 Genta Incorporated Antisense oligomers for inhibiting human papillomaviruses
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
CN1163634A (zh) * 1994-09-22 1997-10-29 麦克公司 编码6a型人乳头瘤病毒的DNA
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
ATE284898T1 (de) * 1999-08-25 2005-01-15 Merck & Co Inc Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
AU2003215244A1 (en) * 2002-02-14 2003-09-04 Curagen Corporation Complexes and methods of using same
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
CN1160463C (zh) * 2002-04-24 2004-08-04 中国医学科学院肿瘤医院肿瘤研究所 人乳头瘤病毒e6/e7融合基因及其高效表达载体和融合蛋白疫苗
US7223408B2 (en) * 2002-10-03 2007-05-29 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
EP1984388B1 (en) * 2006-02-13 2016-07-06 iBio, Inc. Hpv antigens, vaccine compositions, and related methods
EP2594576B1 (en) * 2006-07-28 2015-07-01 The Trustees of The University of Pennsylvania Improved HIV vaccines
EP2390340A3 (en) * 2007-01-30 2012-02-22 Transgene SA vector encoding Papillomavirus E1 and E2 polypeptides with reduced percentage of identity
CN101530615A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 二价重组人乳头瘤病毒疫苗
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
AU2009236585B2 (en) * 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
CN101280316B (zh) * 2008-05-26 2010-06-09 清华大学深圳研究生院 人宫颈癌的一种治疗性疫苗
EP2280728B1 (en) * 2008-05-26 2016-03-02 Cadila Healthcare Limited Combined measles-human papilloma vaccine
CN101591646B (zh) * 2008-05-27 2012-05-30 清华大学深圳研究生院 一种治疗人宫颈癌的树突状细胞疫苗
EP2288380B1 (en) * 2008-06-09 2020-06-03 Bharat Biotech International Limited Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2010054482A1 (en) * 2008-11-12 2010-05-20 Nventa Biopharmaceuticals Corporation Immunogenic human papillomavirus compositions
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
CN102002105B (zh) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Also Published As

Publication number Publication date
KR20240093830A (ko) 2024-06-24
AU2011378812A1 (en) 2014-04-10
ZA201402553B (en) 2015-12-23
CA2848658C (en) 2022-08-02
KR20190056450A (ko) 2019-05-24
AU2017265076A1 (en) 2017-12-14
WO2013055326A2 (en) 2013-04-18
EA033242B1 (ru) 2019-09-30
CN107723299A (zh) 2018-02-23
EP2750703A4 (en) 2015-09-09
CA3161127A1 (en) 2013-04-18
EA201490758A1 (ru) 2014-09-30
WO2013055326A3 (en) 2014-04-10
CN103889450A (zh) 2014-06-25
KR20210019133A (ko) 2021-02-19
CN103889450B (zh) 2017-11-21
KR102373828B1 (ko) 2022-03-14
EP2750703B1 (en) 2018-07-04
AU2011378812B2 (en) 2017-08-24
CN114277038A (zh) 2022-04-05
HK1198940A1 (en) 2015-06-19
KR20220035279A (ko) 2022-03-21
EP3443982A1 (en) 2019-02-20
EP2750703A2 (en) 2014-07-09
AU2017265076B2 (en) 2019-12-05
MX2014004537A (es) 2014-08-01
CN107723299B (zh) 2022-02-01
CA2848658A1 (en) 2013-04-18
KR102216962B1 (ko) 2021-02-18
KR20140076613A (ko) 2014-06-20

Similar Documents

Publication Publication Date Title
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
EA201591688A1 (ru) Усовершенствованные вакцины против вируса папилломы человека и способы их применения
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
TR201908199T4 (tr) HPV'ye karşı aşılar.
MX358762B (es) Procesos que utilizan vlps con cápsides resistentes a hidrolasas.
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
IN2013CN00536A (es)
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
NZ606949A (en) Human papillomavirus e7 antigen compositions and uses thereof
MX365656B (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
MX2018013358A (es) Vacunas para el virus del papiloma humano y metodos para su uso.
MX2024007378A (es) Vacunas para el virus del papiloma humano y metodos para su uso.
MX2015011064A (es) Vacuna contra el virus de la leucemia bovina.
MX2024007379A (es) Vacunas para el virus del papiloma humano y metodos para su uso.
WO2013093629A3 (en) Modular vaccines, methods and compositions related thereto

Legal Events

Date Code Title Description
FG Grant or registration